StressMarq Biosciences has developed an extensive range of fibrillar, oligomeric and monomeric protein preparations for use in neurodegenerative disease research including alpha synuclein, beta synuclein, gamma synuclein, tau, amyloid beta, SOD1 and TTR. Our goal is to be the world leader in the development and supply of active, pathology-inducing protein aggregates to assist scientists with disease model development and accelerate neurodegenerative disease drug discovery.

Gamma synuclein is associated with neurodegenerative diseases as well as certain cancers. Gamma synuclein can seed alpha synuclein aggregation,¹ and its oxidation and aggregation is seen in Dementia with Lewy bodies,² Parkinson’s disease,² and ALS.³

StressMarq manufactures wild-type gamma synuclein fibrils and monomers for use in neurodegenerative disease research.

• Human Recombinant Gamma Synuclein Pre-formed Fibrils (PFFs) | catalog# SPR-459
• Human Recombinant Gamma Synuclein Monomers | catalog# SPR-407

TEM of Active Human Recombinant Gamma Synuclein Protein Pre-formed Fibrils (catalog# SPR-459)

1. Surguchov A: Synucleins: are they two-edged swords? J Neurosci Res 2013, 91(2):16
2. Galvin, J.E. Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains a-, b-, and g-synuclein. Proc Natl Acad Sci USA. 1999 Nov 9; 96(23): 13450–13455.
3. Peters OM, Millership S, Shelkovnikova TA, et al. Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. Neurobiol Dis 2012;48: 124–131.

Supplemental Learning Materials

Technical Support Resources

• Handling Instructions | Synucleins
• Protocols | Neuro Proteins
• Sonication Protocol | PFFs
• Frequently Asked Questions | Neuro Proteins

Selected Publications from the StressMarq Blog

• Gamma Synuclein Aggregation in Neurodegenerative Diseases

Have a question about Gamma Synuclein?